Literature DB >> 3082756

Pseudomonas aeruginosa immunotype 5 polysaccharide-toxin A conjugate vaccine.

S J Cryz, E Furer, J C Sadoff, R Germanier.   

Abstract

Polysaccharide (PS) derived from Pseudomonas aeruginosa immunotype 5 lipopolysaccharide was covalently coupled to toxin A by reductive amination with adipic acid dihydrazide as a spacer molecule. The resulting PS-toxin A conjugate was composed of 27.5% PS and 72.5% toxin A. The conjugate was composed of heterogeneous high-molecular-weight species, all of which possessed an Mr greater than 670,000. The conjugate was nontoxic for mice and nonpyrogenic at a dose of 50 micrograms/kg of body weight when intravenously administered to rabbits. Immunization of rabbits with the conjugate evoked both an antilipopolysaccharide immunoglobulin G (IgG) and an anti-toxin A IgG response. Anticonjugate IgG was capable of neutralizing the cytotoxic effect of toxin A. Immunization of mice with the conjugate increased the mean lethal dose from 4.5 X 10(1) P. aeruginosa for control mice to 9.6 X 10(5) P. aeruginosa for vaccinated mice. Similarly, immunization raised the mean lethal dose for toxin A from 0.2 to 4.67 micrograms per mouse.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3082756      PMCID: PMC262213          DOI: 10.1128/iai.52.1.161-165.1986

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  37 in total

1.  The rapid determination of binding constants for antiviral antibodies by a radioimmunoassay. An analysis of the interaction between hybridoma proteins and influenza virus.

Authors:  M E Frankel; W Gerhard
Journal:  Mol Immunol       Date:  1979-02       Impact factor: 4.407

Review 2.  Roles of exoenzymes and exotoxin in the pathogenicity of Pseudomonas aeruginosa and the development of a new vaccine.

Authors:  J Y Homma
Journal:  Jpn J Exp Med       Date:  1980-06

3.  Lipopolysaccharide pseudomonas vaccine: efficacy against pulmonary infection with Pseudomonas aeruginosa.

Authors:  J E Pennington
Journal:  J Infect Dis       Date:  1979-07       Impact factor: 5.226

4.  Corneal infections in mice with toxin A and elastase mutants of Pseudomonas aeruginosa.

Authors:  D E Ohman; R P Burns; B H Iglewski
Journal:  J Infect Dis       Date:  1980-10       Impact factor: 5.226

5.  Preparation and characterization of detoxified lipopolysaccharide-protein conjugates.

Authors:  R C Seid; J C Sadoff
Journal:  J Biol Chem       Date:  1981-07-25       Impact factor: 5.157

Review 6.  Gram-negative bacteremia. III. Reassessment of etiology, epidemiology and ecology in 612 patients.

Authors:  B E Kreger; D E Craven; P C Carling; W R McCabe
Journal:  Am J Med       Date:  1980-03       Impact factor: 4.965

7.  Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates.

Authors:  H J Jennings; C Lugowski
Journal:  J Immunol       Date:  1981-09       Impact factor: 5.422

8.  Nosocomial infections in the immunocompromised adult.

Authors:  L S Young
Journal:  Am J Med       Date:  1981-02       Impact factor: 4.965

9.  Evidence for the role of toxin A in the pathogenesis of infection with Pseudomonas aeruginosa in humans.

Authors:  A S Cross; J C Sadoff; B H Iglewski; P A Sokol
Journal:  J Infect Dis       Date:  1980-10       Impact factor: 5.226

10.  Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates.

Authors:  R Schneerson; O Barrera; A Sutton; J B Robbins
Journal:  J Exp Med       Date:  1980-08-01       Impact factor: 14.307

View more
  14 in total

1.  Pseudomonas aeruginosa immunotherapy.

Authors:  J E Pennington
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-06       Impact factor: 3.267

2.  Sequence and transcriptional start site of the Pseudomonas aeruginosa outer membrane porin protein F gene.

Authors:  M Duchêne; A Schweizer; F Lottspeich; G Krauss; M Marget; K Vogel; B U von Specht; H Domdey
Journal:  J Bacteriol       Date:  1988-01       Impact factor: 3.490

3.  Passive protection of diabetic rats with antisera specific for the polysaccharide portion of the lipopolysaccharide isolated from Pseudomonas pseudomallei.

Authors:  L E Bryan; S Wong; D E Woods; D A Dance; W Chaowagul
Journal:  Can J Infect Dis       Date:  1994-07

4.  Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans.

Authors:  S J Cryz; E Fürer; A S Cross; A Wegmann; R Germanier; J C Sadoff
Journal:  J Clin Invest       Date:  1987-07       Impact factor: 14.808

5.  Immunization with a Pseudomonas aeruginosa immunotype 5 O polysaccharide-toxin A conjugate vaccine: effect of a booster dose on antibody levels in humans.

Authors:  S J Cryz; J C Sadoff; E Fürer
Journal:  Infect Immun       Date:  1988-07       Impact factor: 3.441

6.  Analysis of Pseudomonas exotoxin activation and conformational changes by using monoclonal antibodies as probes.

Authors:  M Ogata; I Pastan; D FitzGerald
Journal:  Infect Immun       Date:  1991-01       Impact factor: 3.609

7.  Dual-function vaccine for Pseudomonas aeruginosa: characterization of chimeric exotoxin A-pilin protein.

Authors:  R Hertle; R Mrsny; D J Fitzgerald
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.609

8.  Synthesis and immunologic properties in mice of vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides conjugated to Pseudomonas aeruginosa exotoxin A.

Authors:  A Fattom; R Schneerson; S C Szu; W F Vann; J Shiloach; W W Karakawa; J B Robbins
Journal:  Infect Immun       Date:  1990-07       Impact factor: 3.609

9.  Vaccine potential of Pseudomonas aeruginosa O-polysaccharide-toxin A conjugates.

Authors:  S J Cryz; A B Lang; J C Sadoff; R Germanier; E Fürer
Journal:  Infect Immun       Date:  1987-07       Impact factor: 3.609

10.  Synthesis and characterization of a Pseudomonas aeruginosa alginate-toxin A conjugate vaccine.

Authors:  S J Cryz; E Fürer; J U Que
Journal:  Infect Immun       Date:  1991-01       Impact factor: 3.609

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.